Particulate Matter Prompts Baxter's Recall of IV Solutions
Baxter investigates root cause of cellulosic fibers and/or plastics in four lots of IV solutions.
Baxter International Inc. announced a voluntary recall of four lots of intravenous solutions to the hospital/user level due to the presence of particulate matter identified as cellulosic fibers and/or plastics. Baxter reports it received four complaints over a period of six months from customers whose visual inspection identified the appearance of visible particulate matter prior to administration to a patient.
The company says an investigation is underway to determine root cause.
If infused, adverse health consequences of particulate matter could vary depending on the amount of particulate matter injected into the patient, the size of the particles, and the patient’s underlying medical condition. There have been no reported adverse events associated with this issue to date, Baxter reports.
The lots being recalled were distributed worldwide to customers and distributors between February 2013 and June 2014. Baxter has notified customers, who are being directed not to use products from the recalled lots.
This recall is being conducted with the knowledge of the FDA.
Source: FDA and Baxter
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
